U.S. to phase out funding for mRNA vaccine development

2025-08-06 07:05:31 ET More on Moderna, Pfizer, etc. Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript Wall Street Lunch: Trump Threatens 250% Tariff On Pharma Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle Pfizer raises 2025 EPS guidance to $2.90-$3.10 while targeting margin expansion through $7.7B cost savings by 2027 Pfizer CEO says pharma execs discussed Trump's direct-to-consumer demand Read the full article on Seeking Alpha For further details see: U.S. to phase out funding for mRNA vaccine development